share_log

Earnings Call Summary | DaVita(DVA.US) Q1 2024 Earnings Conference

Earnings Call Summary | DaVita(DVA.US) Q1 2024 Earnings Conference

業績電話會議摘要 | DaVita (DVA.US) 2024 年第一季度業績會議
moomoo AI ·  05/03 09:30  · 電話會議

The following is a summary of the DaVita Inc. (DVA) Q1 2024 Earnings Call Transcript:

以下是達維塔公司(DVA)2024年第一季度業績電話會議記錄的摘要:

Financial Performance:

財務業績:

  • DaVita reported Q1 2024 adjusted operating income of $463 million and adjusted earnings per share of $2.38.

  • The company raised their adjusted operating income guidance to a range of $1.875 billion to $1.975 billion owing to improved operational performance and strategic acquisitions.

  • Though initially impacted by a Change Healthcare outage, DaVita has recovered and resumed regular billing and cash collection activities.

  • The company predicts wage inflation around 5% for the year and reported strong cost management with their OI growth being above the long-term indication of 3-7%.

  • DaVita報告稱,2024年第一季度調整後的營業收入爲4.63億美元,調整後的每股收益爲2.38美元。

  • 由於運營業績的改善和戰略收購,該公司將調整後的營業收入預期上調至18.75億美元至19.75億美元之間。

  • 儘管最初受到Change Healthcare中斷的影響,但DaVita已恢復並恢復了常規賬單和現金收款活動。

  • 該公司預測今年的工資通脹率約爲5%,並報告了強勁的成本管理,其OI增長將高於3-7%的長期指標。

Business Progress:

業務進展:

  • DaVita continues to emphasize on improving access to kidney transplants for its patients, and is investing in transplant resources and technology to achieve this goal.

  • The company expanded internationally, pumping $300 million into enhancing its operations in Brazil and Colombia and establishing businesses in Chile and Ecuador.

  • Once recent acquisitions are finalized, DaVita will become the largest dialysis provider in Latin America.

  • The company has registered strong clinical outcomes globally, leading to an 11% reduction in hospitalization rates since 2021.

  • DaVita is working on improving center utilization and plans to close around 30 centers in the net build this year.

  • DaVita繼續強調改善患者獲得腎臟移植的機會,並正在投資移植資源和技術以實現這一目標。

  • 該公司向國際擴張,注資3億美元用於加強其在巴西和哥倫比亞的業務,並在智利和厄瓜多爾建立業務。

  • 最近的收購完成後,DaVita將成爲拉丁美洲最大的透析提供商。

  • 該公司在全球取得了強勁的臨床結果,自2021年以來,住院率下降了11%。

  • DaVita正在努力提高中心利用率,並計劃在今年的淨建中關閉約30箇中心。

More details: DaVita IR

更多詳情: DaVita IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論